360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Sucampo Pharmaceuticals Inc

Type: Company

Name: Sucampo Pharmaceuticals Inc

Nationality: United States

Web Address: http://www.sucampo.com/

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Sucampo to be Added to the NASDAQ Biotechnology Index

Sucampo Pharmaceuticals, Inc.NewsRx.comBy a News Reporter-Staff News Editor at Biotech Week -- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) announced that NASDAQ OMX Group, Inc. (NASDAQ: NDAQ) will include the company in the NASDAQ Biotechnology ... [Published Equities.com - May 22 2013]

Entities: Biotechnology, Sucampo Pharmaceuticals Inc, Index

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Sucampo Pharmaceuticals Inc

Form 4 Sucampo Pharmaceuticals, For: May 17 Filed by: Miele Stanley G

StreetInsider.com - Form 4 Sucampo Pharmaceuticals, For: May 17 Filed by: Miele Stanley G ... [Published Street Insider - May 21 2013]

Entities: Sucampo Pharmaceuticals Inc, Miele

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Shares of Sucampo Pharmaceuticals Under Pressure, Down 3.5%

(Financial News Network On) Sucampo Pharmaceuticals (NASDAQ:SCMP) is one of today's biggest movers, down 3.5% to $9.17. The Dow Jones Industrial Average is now trading 0.3% higher to 15,382 and the S&P is trading fractionally higher to 1,669. Sucam ... [Published Individual.com - May 21 2013]

Entities: Sucampo Pharmaceuticals Inc, Stocks, fractionation, Dow Jones Industrial Average

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Nasdaq OMX Group Inc

NASDAQ OMX Group Adds Sucampo to Its Biotechnology Index

Sucampo Pharmaceuticals, Inc. (SPI) announced that NASDAQ OMX Group, Inc. will include the company in the NASDAQ Biotechnology Index effective prior to market open on Monday, May 20. According to the Company, the NASDAQ Biotechnology Index is designed ... [Published Individual.com - May 20 2013]

Entities: Biotechnology, Index, Nasdaq OMX Group Inc, Sucampo Pharmaceuticals Inc

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Sucampo Pharmaceuticals Q1 net loss increases

Sucampo Pharmaceuticals, Inc., a developer of drugs based on prostones, has reported that net loss for the first quarter ended March 31, 2013 was $3.14 million, or $0.08 loss per share, compared to a net loss of $1.93 million, or $0.05 loss per share, ... [Published Individual.com - May 20 2013]

Entities: Sucampo Pharmaceuticals Inc, amitiza, Doctor of Philosophy, Ryuji Ueno, RESCULA

First reported May 15 2013 - Updated May 16 2013 - 2 reports

Sucampo Pharmaceuticals Inc to be included to the NASDAQ Biotechnology Index

Pharmaceutical company Sucampo Pharmaceuticals Inc (NasdaqGM:SCMP) said on Wednesday that it will be added to NASDAQ OMX Group Inc's (NasdaqGS:NDAQ) NASDAQ Biotechnology Index (NASDAQ:NBI) effective prior to market open on 20 May 2013. The NASDAQ Biotechnology ... [Published Individual.com - May 16 2013]

Entities: Sucampo Pharmaceuticals Inc, Biotechnology, Index

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Sucampo Pharmaceuticals Downgraded by TheStreet to “Hold” (SCMP)

TheStreet cut shares of Sucampo Pharmaceuticals (NASDAQ: SCMP) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, AnalystRatingsNetwork reports.“Sucampo Pharmaceuticals Inc. A (SCMP) has been downgraded by TheStreet ... [Published Mideast Time - May 14 2013]

Entities: Sucampo Pharmaceuticals Inc, Stocks, Maxim Group Inc, Revenue Growth, Stock Prices

First reported May 13 2013 - Updated May 13 2013 - 4 reports

Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20th

BETHESDA, Md. -- Sucampo Pharmaceuticals, Inc. (?Sucampo?) (NASDAQ: SCMP), a global pharmaceutical company, today announced that it will host a meeting to discuss the recent opioid-induced constipation (OIC) indication approval for its flagship product, ... [Published Miami Herald - May 13 2013]

Entities: amitiza, Sucampo Pharmaceuticals Inc, Constipation, opioid

First reported May 08 2013 - Updated May 09 2013 - 2 reports

Sucampo Pharmaceuticals Stock Rating Lowered by TheStreet (SCMP)

Sucampo Pharmaceuticals (NASDAQ: SCMP)The analysts wrote, ?Sucampo Pharmaceuticals Inc. A (SCMP) has been downgraded by TheStreet Ratings from buy to hold. The company?s strengths can be seen in multiple areas, such as its robust revenue growth, expanding ... [Published American Banking News - May 09 2013]

Entities: Sucampo Pharmaceuticals Inc, Earnings Per Share, Maxim Group Inc, Stocks, Stock Prices

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Sucampo Pharmaceuticals, Inc. (SCMP) Reports First Quarter 2013 Financial and Operating Results

Staying up-to-date has never been simpler. Sign up for the today! (âSucampoâ) (NASDAQ: SCMP), a global pharmaceutical company with products available in the United States (U.S.), Japan and Europe, today reported its consolidated financial results for ... [Published BioSpace - May 08 2013]

Entities: Sucampo Pharmaceuticals Inc, United States, Japan

First reported May 01 2013 - Updated May 02 2013 - 2 reports

Sucampo Pharmaceuticals Now Covered by Analysts at MLV Capital (SCMP)

Equities researchers at MLV Capital began coverage on shares of Sucampo Pharmaceuticals (NASDAQ: SCMP) Sucampo Pharmaceuticals (NASDAQ: SCMP) traded down 5.26% on Wednesday, hitting $9.01. Sucampo Pharmaceuticals has a 1-year low of $3.78 and a 1-year ... [Published American Banking News - Stock Ratings - May 02 2013]

Entities: Sucampo Pharmaceuticals Inc, Maxim Group Inc, Cantor Fitzgerald LP

First reported Apr 30 2013 - Updated Apr 30 2013 - 2 reports

Sucampo Pharmaceuticals Announces First Quarter 2013 Results and Operating Highlights Teleconference

Filed under: Investing and WebcastBETHESDA, Md.--( BUSINESS WIRE )-- Sucampo Pharmaceuticals, Inc. ( NAS: SCMP ) , a global pharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial ... [Published Daily Finance - Apr 30 2013]

Entities: Sucampo Pharmaceuticals Inc, Teleconference, Doctor of Philosophy, Ryuji Ueno

Quotes

..."2013 is off to a strong start for Sucampo," said Ryuji Ueno, M D , Ph D , Ph D , Chairman, CEO, and Chief Scientific Officer of Sucampo. "I am very pleased that we have received approval of our sNDA for opioid-induced constipation, the third indication for AMITIZA, and we will receive a $10 million milestone payment from our commercial partner in the second quarter. This quarter we also launched RESCULA and completed additional regulatory filings in Europe for AMITIZA, including filings for OIC in the UK and Switzerland. We are very pleased with these successes and are confident that we are on track to meet our upcoming milestones over the rest of the year."

Sucampo Pharmaceuticals Q1 net loss increases [Published Individual.com - May 20 2013]

...in its role in treating OIC," said Ryuji Ueno, M D , Ph D , Ph D , Chairman, Chief Scientific Officer, and Chief Executive Officer, Sucampo. "With this third indication for AMITIZA, we are pleased to be able to provide physicians an important new option to help treat the unmet needs of their patients."

FDA Approves Supplemental New Drug Application for AMITIZA lubiprostone, the First Oral Treatment ... [Published Pharmacy Choice - May 06 2013]

Galena Biopharma is excited to have him aboard. The company's president and CEO, Mark J Ahn, Ph D , said, "Bill brings an enormous wealth of commercial experience and expertise in pharmaceutical sales, leadership and corporate affairs. . .we look forward to his contributions and guidance in establishing Abstral as the best in class leader in breakthrough cancer pain, as well as preparing for NeuVax commercialization."

Galena Biopharma, Inc. (GALE) Adds William L. Ashton To Board Of Directors [Published Seeking Alpha - May 02 2013]

"Galena has made exceptional progress over the last few years, and I am excited to join the Board of Directors as the company initiates commercialization. With NeuVax enrolling its Phase 3 trial and the commercialization of Abstral expected this year, I look forward to providing my support and guidance as we work to enhance the treatment of cancer patients" added William L Ashton

RXI PHARMACTCLS : William L. Ashton Joins Galena Biopharma's Board of Directors [Published 4 Traders - May 01 2013]

More Content

sort by: Date \| Relevance
Sucampo to be Added to the NASDAQ Biotechnology... [Published Equities.com - May 22 2013]
Form 4 Sucampo Pharmaceuticals, For: May 17 Fil... [Published Street Insider - May 21 2013]
Shares of Sucampo Pharmaceuticals Under Pressur... [Published Individual.com - May 21 2013]
Sucampo Pharmaceuticals Q1 net loss increases [Published Individual.com - May 20 2013]
NASDAQ OMX Group Adds Sucampo to Its Biotechnol... [Published Individual.com - May 20 2013]
Sucampo Pharmaceuticals Makes a Move: Down 1.6% [Published Individual.com - May 16 2013]
Sucampo Pharmaceuticals Inc to be included to t... [Published Individual.com - May 16 2013]
Form 4 Sucampo Pharmaceuticals, For: May 13 Fil... [Published Street Insider - May 15 2013]
Form 4 Sucampo Pharmaceuticals, For: May 13 Fil... [Published Street Insider - May 15 2013]
Form 4 Sucampo Pharmaceuticals, For: May 13 Fil... [Published Street Insider - May 15 2013]
Sucampo Pharmaceuticals, Inc. (SCMP) to be Adde... [Published BioSpace - May 15 2013]
Sucampo to be Added to the NASDAQ Biotechnology... [Published Business Wire - May 15 2013]
Sucampo to be Added to the NASDAQ Biotechnology... [Published Business Wire Professional Services News - May 15 2013]
Sucampo to be Added to the NASDAQ Biotechnology... [Published Business Wire Health News - May 15 2013]
Sucampo Pharmaceuticals Downgraded by TheStreet... [Published Mideast Time - May 14 2013]
Semi-Annual Changes to the NASDAQ Biotechnology... [Published BizWire Express - May 13 2013]
Sucampo Pharmaceuticals to Host Update on AMITI... [Published Miami Herald - May 13 2013]
Sucampo Pharmaceuticals to Host Update on AMITI... [Published NewsBlaze - May 13 2013]
Sucampo Pharmaceuticals to Host Update on AMITI... [Published Zecco - May 13 2013]
Sucampo Pharmaceuticals to Host Update on AMITI... [Published Business Wire Science: Science News - May 13 2013]
Sucampo Pharmaceuticals to Host Update on AMITI... [Published Business Wire Health News - May 13 2013]
Sucampo Pharmaceuticals Posts 1Q 2013 Financial... [Published Individual.com - May 13 2013]
Sucampo Pharmaceuticals Up 63.0% Since SmarTren... [Published Individual.com - May 10 2013]
Sucampo Pharmaceuticals PT Raised to $11.00 at ... [Published American Banking News - May 10 2013]
Sucampo Pharmaceuticals Stock Rating Lowered by... [Published American Banking News - May 09 2013]
Sucampo's Stock Could Reach $12, Says Maxim's S... [Published BioPortfolio - May 09 2013]
Sucampo's Stock Could Reach $12, Says Maxim's S... [Published Seeking Alpha - May 09 2013]
Equities Research Analysts’ Downgrades for May,... [Published American Banking News - May 09 2013]
Sucampo Pharmaceuticals Lowered to Underperform... [Published American Banking News - Stock Ratings - May 08 2013]
Stock Analysts’ Downgrades for May, 8th (AGII, ... [Published American Banking News - May 08 2013]

Blogs

sort by: Date \| Relevance
Who can you meet at Partnerships in Clinical Tr... [Published Partnerships in Clinical Trials - Apr 01 2013] Partnerships in Clinical Trials 2013 brings together 1500+ clinical decision makers for four days of insightful content, connections and knowledge sharing that pushes the boundaries of drug development and provides you with an enhanced roadmap to ...
Nothing Terrific About Boise and 4 More Analyst... [Published Wall St. Cheat Sheet - Mar 19 2013] Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up ...
RESCULA (Unoprostone Isopropyl) Solution/ Drops... [Published DailyMed Drug Label Updates for the last seven ... - Jan 16 2013] Updated Date: Jan 10, 2013 EST ...
RESCULA (Unoprostone Isopropyl) Solution/ Drops... [Published DailyMed Drug Label Updates for the last seven ... - Jan 10 2013] Updated Date: Jan 10, 2013 EST ...
Abbott Japan makes $15m milestone payment to Su... [Published PBR - News - Dec 13 2012] Sucampo AG, a subsidiary of Sucampo Pharmaceuticals, has earned a milestone payment worth $15m from Abbott Japan on the first sale of chronic constipation medication, Amitiza capsule 24μg, in Japan. ...

Press Releases

sort by: Date \| Relevance
Sucampo to be Added to the NASDAQ Biotechnology... [Published Business Wire - May 15 2013]
Sucampo to be Added to the NASDAQ Biotechnology... [Published Business Wire Professional Services News - May 15 2013]
Sucampo to be Added to the NASDAQ Biotechnology... [Published Business Wire Health News - May 15 2013]
Sucampo Pharmaceuticals to Host Update on AMITI... [Published Business Wire Science: Science News - May 13 2013]
Sucampo Pharmaceuticals to Host Update on AMITI... [Published Business Wire Health News - May 13 2013]